AstraZeneca Share Price (AZN)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
AstraZeneca	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-23.00p	-0.38%	6,020.00p	495,788	13:27:06

Bid Price		Offer Price	High Price	Low Price	Open Price
6,019.00p		6,021.00p	6,050.00p	5,967.00p	6,050.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	16,632.67	1,648.83	175.47	32.0	76,250.1

Related Shares
GlaxoSmithKline (GSK), Shire (SHP), Venn Life (VENN), Port Erin (PEBI)

AstraZeneca (AZN) Latest News (6)

AstraZeneca News

Date	Time	Source	Headline
18/12/2018	13:23	DJN	Big Pharma Wins Drug Approval in China Ahead of West for First Time
18/12/2018	09:55	DJN	AstraZeneca's Roxadustat Receives China Approval
18/12/2018	09:36	ALNC	AstraZeneca Secures Marketing Authorisation Of Anaemia Drug In China
18/12/2018	09:11	ALNCF	Alliance News Flash Headline
18/12/2018	09:09	UKREG	AstraZeneca PLC Roxadustat approved in China for the treatment of
14/12/2018	08:23	ALNC	AstraZeneca Appoints CUHK Clinical Oncology Department Chair To Board
14/12/2018	07:01	UKREG	AstraZeneca PLC Directorate Change
11/12/2018	13:15	ALNC	Circassia Pharma To Acquire Full US Tudorza Rights From AstraZeneca
11/12/2018	13:09	DJN	Circassia Pharmaceuticals to Acquire Full Tudorza Commercial Rights in US
11/12/2018	06:50	ALNC	Dr Reddy's Launches Over-The-Counter Version Of AstraZeneca's Prilosec

More AstraZeneca News

AstraZeneca Takeover Rumours

AstraZeneca (AZN) Share Charts

1 Year AstraZeneca Chart

1 Month AstraZeneca Chart

Intraday AstraZeneca Chart

AstraZeneca (AZN) Discussions and Chat

AstraZeneca Forums and Chat

Date	Time	Title	Posts
04/12/2018	11:38	AstraZeneca	2,113
15/10/2018	17:31	* AstraZeneca *	360
25/7/2018	19:56	AstraZeneca (AZN) One to Watch on Thursday	-
25/5/2018	13:38	AstraZeneca (AZN) Promising Findings	-
03/4/2017	19:08	Potential Reaction on AstraZeneca (AZN)	-

Add a New Thread

AstraZeneca (AZN) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
13:27:06	6,020.00	94	5,658.80	AT
13:27:04	6,022.00	825	49,681.50	O
13:26:42	6,021.00	60	3,612.60	AT
13:26:26	6,022.00	27	1,625.94	AT
13:26:26	6,022.00	104	6,262.88	AT

View all AstraZeneca trades in real-time

AstraZeneca (AZN) Top Chat Posts

Date	Subject
18/12/2018 08:20	AstraZeneca Daily Update: AstraZeneca is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for AstraZeneca was 6,043p. AstraZeneca has a 4 week average price of 5,886p and a 12 week average price of 5,518p. The 1 year high share price is 6,432p while the 1 year low share price is currently 4,544.50p. There are currently 1,266,613,555 shares in issue and the average daily traded volume is 2,011,082 shares. The market capitalisation of AstraZeneca is £76,262,802,146.55. Read Full Thread Reply
18/7/2018 11:01	bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks! Read Full Thread Follow Reply
08/10/2017 11:51	cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance \| Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment Read Full Thread Follow Reply
30/7/2017 18:12	nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend." Read Full Thread Follow Reply
28/7/2017 14:10	minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh? Read Full Thread Follow Reply
27/7/2017 09:46	minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675. Read Full Thread Follow Reply
27/7/2017 09:10	steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend. Read Full Thread Follow Reply
27/1/2017 09:02	steeplejack: Goldmans issued a sell note on the 24 Jan with a £39 share price target.Thats probably still washing through. Read Full Thread Follow Reply
20/1/2017 17:26	philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/ Read Full Thread Follow Reply
06/12/2016 09:19	bili1946: I have looked through the last months target share price from 12 brokers.....range from £46 to £60? Today,s latest £55? Read Full Thread Follow Reply
02/5/2014 07:43	harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on . Read Full Thread Follow Reply

AstraZeneca share price data is direct from the London Stock Exchange

Your Recent History

LSE

AZN

AstraZenec..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20181218 13:42:20